Clinical Trial Finds Osimertinib Combined with Chemotherapy Extends Survival in EGFR-Mutated Advanced Lung Cancer
A groundbreaking Phase III trial demonstrates that combining osimertinib with chemotherapy significantly extends overall survival in patients with EGFR-mutated advanced lung cancer, potentially establishing a new standard of care.
A recent Phase III clinical trial, known as FLAURA2, has demonstrated that combining osimertinib with chemotherapy significantly improves overall survival in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC). The trial's final results reveal that this combination therapy offers a substantial survival benefit over osimertinib alone.
The FLAURA2 study involved 557 patients who had not received prior treatment for their condition and had confirmed EGFR mutations. Participants were randomized in a 1:1 ratio to receive either osimertinib with chemotherapy—comprising pemetrexed along with cisplatin or carboplatin—or osimertinib alone. The primary goal was to assess progression-free survival, with overall survival as a key secondary endpoint.
With a median follow-up of approximately 57% maturity, the group receiving both osimertinib and chemotherapy showed a median overall survival of 47.5 months, significantly higher than the 37.6 months observed in the monotherapy group. The 36-month survival rate was 63% with the combination therapy compared to 51% with osimertinib alone. These results were consistent across various patient subgroups.
Safety profiles for the combination treatment remained manageable, with side effects aligning with the known safety profiles of the individual treatments. Notably, adverse events leading to discontinuation occurred in 12% of patients on the combination arm versus 7% on monotherapy.
These findings, presented at the IASLC 2025 World Conference on Lung Cancer, suggest that adding chemotherapy to osimertinib could establish a new standard of care for patients with EGFR-mutated advanced NSCLC. Dr. David Planchard from Institut Gustave Roussy emphasized that this combination extends survival while maintaining a manageable safety profile, reinforcing the role of osimertinib as the backbone of first-line therapy in this setting.
Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, is currently preferred as a first-line treatment. The trial results support augmenting this therapy with chemotherapy for a significant overall survival advantage, potentially reshaping treatment guidelines for this patient population.
For more details, visit MedicalXpress.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Tragic Losses in Mexican Measles Outbreak as Children Among Four Victims
Mexican measles outbreak has claimed four lives in 2025, including three children, highlighting the critical need for vaccination and public health efforts near the US border.
Molecular Insights into Comorbidities in People Living with HIV: A Big Data Approach
A groundbreaking big data study uncovers molecular mechanisms driving comorbidities in people living with HIV, opening new avenues for targeted therapies and personalized medicine.
FDA Approves Innovative Eye Implant to Combat Vision Loss in Rare Retina Disease
The FDA has approved ENCELTO, a groundbreaking eye implant that slows vision loss in patients with macular telangiectasia type 2, offering hope through advanced neuroprotective therapy.
Critics Challenge MAHA Report for Undermining Success of Asthma Medications in Children
Experts criticise the MAHA report for undermining the vital role of asthma medications in children's health, warning of potential policy and access implications.